P3–295: Mass production neurohistology and contemporary staining techniques accelerate and ADD efficacy to Alzheimer's disease research

govern the degradation of normal and mutant tau species. Methods: We have examined the accumulation of tau using cell culture models and in the rTg4510 inducible tau mouse line, using both pharmacological and molecular techniques to manipulate proteasomal and lysosomal pathways. Results: Our studies show that both proteasomal and lysosomal pathways regulate tau degradation. We are currently examing the effects of inhibiting these pathways in the rTg4510 mouse line to determine if impaired activity can accelerate tau pathology in vivo, and are characterizing the clearance of early tau pathology in rTg4510 mice following tau repression. Conclusions: Our data suggest that both proteasomal and lysosomal pathways are important in mediating clearance of tau. We anticipate that impaired proteasomal or lysosomal degradation of tau species will have markedly different effects on the development of tau pathology and clearance of early tau species in rTg4510 transgenic mice.